Investigators at Kaiser Permanente Los Angeles Medical Center Have Reported New Data on Hormones (Prior testosterone use does not appear to impact oocyte cryopreservation outcomes in transgender patients: findings from a multicenter health …): Hormones

2025 OCT 17 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- New research on Hormones is the subject of a report. According to news reporting from Los Angeles, California, by NewsRx journalists, research stated, “To compare the outcomes of oocyte cryopreservation in transgender patients with and without prior testosterone use. Retrospective cohort study. Transmasculine/non-binary patients assigned female at birth who were referred for fertility preservation from January 2012 to March 2024 at a multicenter health maintenance organization.”

The news correspondents obtained a quote from the research from Kaiser Permanente Los Angeles Medical Center, “Gender-affirming hormone therapy with testosterone. The primary outcome measure was the number of mature oocytes collected. Secondary outcomes included the total number of oocytes, percentage of mature to total oocytes, total dose of gonadotropins used, baseline antimullerian hormone, baseline antral follicle count, and baseline endometrial thickness. Data from 50 transgender oocyte cryopreservation cycles were analyzed in the time period studied. A total of 34 subjects (68%) had no exposure to testosterone, whereas prior testosterone use was reported in 16 subjects (32%). The mean duration of testosterone was 4.1 ± 2.6 years. Testosterone was discontinued 3 weeks to 3 months before cycle start. There were no significant differences in baseline demographics, such as age and body mass index, between the two patient groups. The total number of oocytes retrieved was statistically the same between transgender patients with prior testosterone use (17.3 ± 10.1) and those without (21.3 ± 10.1). Additionally, there were no differences in the number of mature oocytes (12.0 ± 7.5 vs. 16.1 ± 9.1) or ratio of mature/total oocytes between the two groups (72.3% ± 18.3% vs. 70.9% ± 22.4%). Secondary outcomes such as baseline antral follicle count, baseline antimullerian hormone, total dose of gonadotropins used, and baseline endometrial thickness demonstrated no significant difference between the two study groups. Our study suggests that prior testosterone use does not appear to impact oocyte cryopreservation outcomes in transgender patients.”

According to the news reporters, the research concluded: “As a growing number of transgender patients seek fertility care, there is a need for evidence-based research that can guide clinical practice and empower this population to realize their aspirations for parenthood.”

For more information on this research see: Prior testosterone use does not appear to impact oocyte cryopreservation outcomes in transgender patients: findings from a multicenter health maintenance organization. F&S Reports, 2025;6(3):328-334.

Our news journalists report that additional information may be obtained by contacting Snunit Ben-Ozer, Dept. of Reproductive Endocrinology and Infertility, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California. Additional authors for this research include Natasha Raj-Derouin, Amy Shah Dhesi, Tracy Harrison, Ashley Kim, Mandana Ghahremani, Sami Jabara and Marsha Baker.

(Our reports deliver fact-based news of research and discoveries from around the world.)